NO960393L - Heterocyclic phenyl compounds as COX-2 inhibitors - Google Patents
Heterocyclic phenyl compounds as COX-2 inhibitorsInfo
- Publication number
- NO960393L NO960393L NO960393A NO960393A NO960393L NO 960393 L NO960393 L NO 960393L NO 960393 A NO960393 A NO 960393A NO 960393 A NO960393 A NO 960393A NO 960393 L NO960393 L NO 960393L
- Authority
- NO
- Norway
- Prior art keywords
- cox
- inhibitors
- phenyl compounds
- heterocyclic phenyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
- C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Abstract
Oppfinnelsen omfatter den nye forbindelse av formel (I) (l) som er anvendbar ved behandling av syk- looksygenase-2-formidlede sykdommer. Oppfinnelsen omfatter også visse far- masøytiske preparater for behandling av syklooksygenase-2-formidlede sykdommer omfattende forbindelser av formel (I).The invention encompasses the novel compound of formula (I) (1) which is useful in the treatment of disease sygenase-2-mediated diseases. The invention also encompasses certain pharmaceutical compositions for the treatment of cyclooxygenase-2-mediated diseases comprising compounds of formula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/179,467 US5474995A (en) | 1993-06-24 | 1994-01-10 | Phenyl heterocycles as cox-2 inhibitors |
PCT/CA1994/000688 WO1995018799A1 (en) | 1994-01-10 | 1994-12-19 | Phenyl heterocycles as cox-2 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO960393D0 NO960393D0 (en) | 1996-01-30 |
NO960393L true NO960393L (en) | 1996-07-09 |
Family
ID=22656713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO960393A NO960393L (en) | 1994-01-10 | 1996-01-30 | Heterocyclic phenyl compounds as COX-2 inhibitors |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0739340A1 (en) |
JP (1) | JP2788677B2 (en) |
CN (1) | CN1143365A (en) |
AU (1) | AU1269495A (en) |
BG (1) | BG63082B1 (en) |
BR (1) | BR9408478A (en) |
CA (1) | CA2180651A1 (en) |
FI (1) | FI108792B (en) |
HU (1) | HUT74986A (en) |
NO (1) | NO960393L (en) |
SG (1) | SG43841A1 (en) |
WO (1) | WO1995018799A1 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9420616D0 (en) * | 1994-10-12 | 1994-11-30 | Merck Sharp & Dohme | Method, compositions and use |
AU715676B2 (en) * | 1993-03-12 | 2000-02-10 | Merck Frosst Canada & Co. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
US5840746A (en) * | 1993-06-24 | 1998-11-24 | Merck Frosst Canada, Inc. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5585504A (en) * | 1994-09-16 | 1996-12-17 | Merck & Co., Inc. | Process of making cox-2 inhibitors having a lactone bridge |
ATE268176T1 (en) * | 1995-07-19 | 2004-06-15 | Merck & Co Inc | TREATMENT METHODS FOR COLON ADENOMAS |
US5968974A (en) | 1995-07-19 | 1999-10-19 | Merck & Co., Inc. | Method of treating colonic adenomas |
US6593361B2 (en) | 1995-07-19 | 2003-07-15 | Merck & Co Inc | Method of treating colonic adenomas |
BR9709097A (en) * | 1996-05-17 | 1999-08-03 | Merck & Co Inc | Pharmaceutical composition for the treatment of diseases mediated by cyclooxygenase process to treat an inflammatory disease susceptible to treatment with an anti-inflammatory agent in the steroid use and oral form of unit dose |
AU775030B2 (en) * | 1996-05-17 | 2004-07-15 | Merck Frosst Company | Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases |
GB9615867D0 (en) * | 1996-07-03 | 1996-09-11 | Merck & Co Inc | Process of preparing phenyl heterocycles useful as cox-2 inhibitors |
US5939069A (en) * | 1996-08-23 | 1999-08-17 | University Of Florida | Materials and methods for detection and treatment of immune system dysfunctions |
US6004960A (en) * | 1997-03-14 | 1999-12-21 | Merck Frosst Canada, Inc. | Pyridazinones as inhibitors of cyclooxygenase-2 |
ES2224366T3 (en) * | 1997-03-14 | 2005-03-01 | MERCK FROSST CANADA & CO. | PIRIDAZINONAS AS INHIBITORS OF CICLOOXIGENASA-2. |
US6136831A (en) * | 1997-04-11 | 2000-10-24 | Grelan Pharmaceutical Co., Ltd. | Pyrazole derivatives and COX inhibitors containing them |
AU7237998A (en) * | 1997-05-16 | 1998-12-08 | Chugai Seiyaku Kabushiki Kaisha | Indole derivatives and mono- and diazaindole derivatives |
CN1155600C (en) | 1997-09-05 | 2004-06-30 | 葛兰素集团有限公司 | 2,3-diaryl-pyrazolo [1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2 (cox-2) inhibitors |
NZ333399A (en) | 1997-12-24 | 2000-05-26 | Sankyo Co | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis |
SA99191255B1 (en) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | celecoxib compounds |
ES2328446T5 (en) | 2000-02-04 | 2014-02-27 | Children's Hospital Research Foundation | Use of lysosomal acid lipase to treat atherosclerosis and associated diseases |
US6465509B2 (en) * | 2000-06-30 | 2002-10-15 | Merck Frosst Canada & Co. | Pyrones as inhibitors of cyclooxygenase-2 |
DE10133665A1 (en) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carboxylic acid derivatives, medicaments containing these compounds, their use and preparation |
SI3072978T1 (en) | 2002-05-09 | 2018-11-30 | The Brigham And Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker |
AU2003247622A1 (en) | 2002-06-27 | 2004-01-19 | Nitromed, Inc. | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
DK2384753T3 (en) | 2003-08-29 | 2016-04-11 | Brigham & Womens Hospital | Hydantoin derivatives as inhibitors of cell necrosis |
KR20050051729A (en) * | 2003-11-28 | 2005-06-02 | 일양약품주식회사 | Process for preparing phenyl heterocycles as a cyclooxygenase-2 inhibitor |
DE102004027912A1 (en) | 2004-06-09 | 2005-12-29 | Grünenthal GmbH | Substituted cyclopentene compounds |
WO2006042192A2 (en) | 2004-10-06 | 2006-04-20 | The Brigham And Womens's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
US7521435B2 (en) | 2005-02-18 | 2009-04-21 | Pharma Diagnostics, N.V. | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same |
EP2808015A1 (en) | 2005-05-31 | 2014-12-03 | Mylan Laboratories, Inc | Compositions comprising nebivolol |
US8119358B2 (en) | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
JP5322917B2 (en) | 2006-03-15 | 2013-10-23 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | Use of gelsolin for the diagnosis and treatment of inflammatory diseases |
WO2007146229A2 (en) | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
AU2008242764B2 (en) | 2007-04-18 | 2013-10-24 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
GB2460915B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
CN103037829A (en) | 2010-02-01 | 2013-04-10 | 儿童医院 | Remote ischemic conditioning for treatment and prevention of restenosis |
CN102939054A (en) | 2010-03-31 | 2013-02-20 | 儿童医院 | Use of remote ischemic conditioning to improve outcome after myocardial infarction |
US9265772B2 (en) | 2012-05-11 | 2016-02-23 | Reset Therapeutics, Inc. | Carbazole-containing sulfonamides as cryptochrome modulators |
EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
TWI690521B (en) | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators |
US20220047518A1 (en) | 2018-09-19 | 2022-02-17 | Moderna TX, Inc. | Peg lipids and uses thereof |
CN112996854A (en) | 2018-09-19 | 2021-06-18 | 摩登纳特斯有限公司 | High purity PEG lipids and uses thereof |
WO2020106522A1 (en) | 2018-11-21 | 2020-05-28 | Tremeau Pharmaceuticals, Inc. | Purified forms of rofecoxib, methods of manufacture and use |
US10945992B1 (en) | 2019-11-13 | 2021-03-16 | Tremeau Pharmaceuticals, Inc. | Dosage forms of rofecoxib and related methods |
US11161833B1 (en) | 2021-04-09 | 2021-11-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0388909A3 (en) * | 1989-03-22 | 1991-05-08 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same |
EP0524979A4 (en) * | 1990-04-17 | 1993-03-10 | Allergan, Inc. | 2(5h)-furanones substituted in the 5 and or in the 4 position, as anti-inflammatory agents |
GB9012936D0 (en) * | 1990-06-11 | 1990-08-01 | Fujisawa Pharmaceutical Co | Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
ATE160345T1 (en) * | 1993-01-15 | 1997-12-15 | Searle & Co | 3,4-DIARYLTHIOPHENES AND ANALOGS THEREOF AND THEIR USE AS ANTI-INFLAMMATORY AGENTS |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
KR960703901A (en) * | 1993-08-19 | 1996-08-31 | 로즈 암스트롱 | Substituted 2 (5H) furanone, 2 (5H) thiophenone and 2 (5H) pyrrolone derivatives, methods for their preparation and their use as endothelin antagonists (Substituted 2 (5H) Furanone, 2 (5H) Thiophenone and 2 (5H) Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists) |
-
1994
- 1994-12-19 SG SG1996002006A patent/SG43841A1/en unknown
- 1994-12-19 BR BR9408478A patent/BR9408478A/en not_active Application Discontinuation
- 1994-12-19 AU AU12694/95A patent/AU1269495A/en not_active Abandoned
- 1994-12-19 HU HU9601875A patent/HUT74986A/en not_active Application Discontinuation
- 1994-12-19 JP JP7518234A patent/JP2788677B2/en not_active Expired - Fee Related
- 1994-12-19 WO PCT/CA1994/000688 patent/WO1995018799A1/en active IP Right Grant
- 1994-12-19 EP EP95903727A patent/EP0739340A1/en not_active Withdrawn
- 1994-12-19 CA CA002180651A patent/CA2180651A1/en not_active Abandoned
- 1994-12-19 CN CN94195045A patent/CN1143365A/en active Pending
-
1996
- 1996-01-30 NO NO960393A patent/NO960393L/en not_active Application Discontinuation
- 1996-02-12 BG BG100350A patent/BG63082B1/en unknown
- 1996-07-09 FI FI962800A patent/FI108792B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HUT74986A (en) | 1997-03-28 |
JP2788677B2 (en) | 1998-08-20 |
FI962800A0 (en) | 1996-07-09 |
FI108792B (en) | 2002-03-28 |
EP0739340A1 (en) | 1996-10-30 |
HU9601875D0 (en) | 1996-09-30 |
BG63082B1 (en) | 2001-03-30 |
AU1269495A (en) | 1995-08-01 |
SG43841A1 (en) | 1997-11-14 |
JPH09506631A (en) | 1997-06-30 |
BG100350A (en) | 1996-12-31 |
BR9408478A (en) | 1997-08-26 |
CA2180651A1 (en) | 1995-07-13 |
CN1143365A (en) | 1997-02-19 |
FI962800A (en) | 1996-09-06 |
NO960393D0 (en) | 1996-01-30 |
WO1995018799A1 (en) | 1995-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO960393L (en) | Heterocyclic phenyl compounds as COX-2 inhibitors | |
DK0705254T3 (en) | Phenyl heterocyclic compounds as cyclooxygenase-2 inhibitors | |
DK0863891T3 (en) | (Methylsulfonyl) phenyl 2- (5H) -furanones as COX2 inhibitors | |
DE69529690T2 (en) | DIARYL-2 (5H) -FUARANONE AS COX-2 INHIBITORS | |
DE69514813T2 (en) | BICYCLIC DIARYLHETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | |
DK0828724T3 (en) | 5-oxygenated diaryl-2- (5H) -furanones as COX-2 inhibitors | |
NO20032801L (en) | Thiazole derivatives for the treatment of PPAR-related disorders | |
DE69616749D1 (en) | ARYL SUBSTITUTED 5.5 LINKED AROMATIC NITRO COMPOUNDS AS AN ANTI-FLAMMING AGENTS | |
DE60329316D1 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
NO20056192L (en) | Capase inhibitors and their use | |
ES2171723T3 (en) | 3,4-DIARIL-2-HYDROXI-2,5-DIHYDROFURANS AS COX-2 INHIBITORS PROPHARMS. | |
AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
ATE223376T1 (en) | BISARYLCYCLOBUTENE DERIVATIVES AS CYCLOOXYGENASE INHIBITORS | |
NO983511L (en) | Diphenylstilbenes as prodrugs for COX-2 inhibitors | |
EA200101109A1 (en) | DERIVATIVES 1-TRIFTOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHILKHROMAN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |